RecruitingNot ApplicableNCT07079592

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension: A Randomized Controlled Trial


Sponsor

National Defense Medical Center, Taiwan

Enrollment

8,666 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to validate the use of an artificial intelligence-enabled electrocardiogram (AI-ECG) to screen for elevated PAP. We hypothesize that the AI-ECG model can early identify patients with pulmonary hypertension in high-risk patients, prompting further evaluation through echocardiography, potentially resulting in improving cardiovascular outcomes.


Eligibility

Min Age: 50 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a computer program that reads heart tracings (ECGs) can detect a type of high blood pressure in the lungs called pulmonary hypertension — before symptoms become serious. You may be eligible if: - You are a man or woman between 50 and 85 years old - You have had at least one standard 12-lead heart tracing (ECG) done within the past 3 months You may NOT be eligible if: - You have already been diagnosed with pulmonary hypertension (any type) - You have been diagnosed with certain heart muscle conditions, such as hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy - You have previously had a heart, lung, or combined heart-lung transplant - An echocardiogram (heart ultrasound) has already shown high pressure in your lung arteries (above 50 mmHg) - You have had an echocardiogram within 3 months before your ECG that was used for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTAI-ECG Guidance

Participants undergo screening using the AI-ECG system. Those identified as high-risk for pulmonary hypertension receive echocardiography to confirm the diagnosis and guide subsequent management.


Locations(1)

National Defense Medical Center

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07079592


Related Trials